UK approves AstraZeneca’s antibody-based COVID treatment

Mar 17,2022: Mar 17,2022: Britain’s medicines regulator said on Thursday it had approved AstraZeneca’s antibody-based treatment to prevent COVID-19 in people whose immune response is poor.
The decision to grant approval for the treatment was endorsed by the government’s independent expert scientific advisory body after reviewing the evidence, the Medicines and Healthcare products Regulatory Agency (MHRA) said.
AstraZeneca’s antibody cocktail, branded Evusheld, has already been authorized in the United States to prevent COVID-19 infections in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines.